FUNDAMENTALS · Fundamentals · HK Healthcare

Dawnrays Pharmaceutical (Holdings) (2348) Fundamentals 2026 — P/E 6.2x, Revenue Analysis | SniperIQ

Dawnrays Pharmaceutical (Holdings) (2348) is a HK-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK

.5B, trading at HK
.00 on the HKSE. This SniperIQ fundamentals page covers Dawnrays Pharmaceutical (Holdings)'s valuation (P/E 6.2x, P/B 0.4x), profitability (net margin 17.4%), revenue (¥1.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
.5B
P/E (TTM)6.2x
Net Margin17.4%
Revenue (FY25)¥1.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Dawnrays Pharmaceutical (Holdings)'s market cap?

Dawnrays Pharmaceutical (Holdings) (2348) has a market capitalization of approximately HK

.5B, trading at HK
.00 on the HKSE. Market cap moves with the live share price.

What is Dawnrays Pharmaceutical (Holdings)'s P/E ratio?

Dawnrays Pharmaceutical (Holdings)'s trailing twelve-month P/E ratio is 6.2x, with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Dawnrays Pharmaceutical (Holdings)?

Dawnrays Pharmaceutical (Holdings) runs a net profit margin of 17.4%, a gross margin of 45.3%, and an operating margin of 18.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Dawnrays Pharmaceutical (Holdings) generate?

Dawnrays Pharmaceutical (Holdings) reported revenue of ¥1.2B for fiscal year 2025, with net income of ¥214M and earnings per share (EPS) of 0.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Dawnrays Pharmaceutical (Holdings) pay a dividend?

Dawnrays Pharmaceutical (Holdings) offers a trailing dividend yield of about 6.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Dawnrays Pharmaceutical (Holdings) financially healthy?

Dawnrays Pharmaceutical (Holdings) carries a debt-to-equity ratio of 0.02x and a current ratio of 4.64x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Dawnrays Pharmaceutical (Holdings) a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dawnrays Pharmaceutical (Holdings) (2348) the key facts are: market cap HK

.5B, P/E 6.2x, revenue ¥1.2B, 52-week range 0.98-1.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Dawnrays Pharmaceutical (Holdings)'s full fundamentals live

Get Dawnrays Pharmaceutical (Holdings)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Septerna (SEPN) fundamentals · Rapport Therapeutics, Inc. Common Stock (RAPP) fundamentals · Bicara Therapeutics Inc. Common Stock (BCAX) fundamentals · Healthlead Public (HL) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons